

119<sup>TH</sup> CONGRESS  
1<sup>ST</sup> SESSION

# H. R. 6789

To amend title 18, United States Code, to require the Bureau of Prisons to ensure the availability of opioid antagonists at Federal correctional facilities.

---

## IN THE HOUSE OF REPRESENTATIVES

DECEMBER 17, 2025

Mrs. FOUSHEE (for herself, Mrs. MCBATH, and Mr. JOHNSON of Georgia) introduced the following bill; which was referred to the Committee on the Judiciary

---

## A BILL

To amend title 18, United States Code, to require the Bureau of Prisons to ensure the availability of opioid antagonists at Federal correctional facilities.

1       *Be it enacted by the Senate and House of Representa-*  
2       *tives of the United States of America in Congress assembled,*

3       **SECTION 1. SHORT TITLE.**

4       This Act may be cited as the “Federal Prisons  
5       Naloxone Access Act of 2025”.

6       **SEC. 2. AVAILABILITY OF OPIOID ANTAGONISTS.**

7       Chapter 303 of title 18, United States Code, is  
8       amended—

9               (1) by adding at the end the following:

1 **“§ 4052. Availability of opioid antagonists**

2 “(a) IN GENERAL.—The Director of the Bureau of  
3 Prisons shall ensure that—

4 “(1) an adequate number of opioid antagonist  
5 kits are maintained at each correctional facility ad-  
6 ministered by the Bureau, and such kits are avail-  
7 able in—

8 “(A) medical housing units;

9 “(B) staff breakrooms; and

10 “(C) visiting areas, living quarters, recre-  
11 ation spaces, dining halls, housing units, work  
12 and program locations, hallways, corridor posts,  
13 security checkpoints, any area where incarcerated  
14 people congregate, and educational and re-  
15 ligious areas;

16 “(2) that each such opioid antagonist kit is  
17 maintained appropriately, including storage—

18 “(A) in appropriate conditions at room  
19 temperature and out of direct sunlight; and

20 “(B) in a secure area that is accessible to  
21 personnel of the facility;

22 “(3) that incarcerated persons are able to ac-  
23 cess such opioid antagonist kits to administer to  
24 those who are overdosing; and

1           “(4) in the case of any opioid antagonist kit  
2           with an expiration date, that such kit is regularly  
3           checked to determine if there is a need to replace it.

4           “(b) TRAINING.—The Director shall ensure that the  
5           personnel and incarcerated persons of each correctional fa-  
6           cility administered by the Bureau receive annual training  
7           from medical staff of the Bureau of Prisons on the admin-  
8           istration of opioid antagonists, including guidance on rec-  
9           ognizing any signs or symptoms of an opioid overdose.

10          “(c) DOCUMENTATION.—The Director shall ensure  
11          that, with regard to each administration of an opioid an-  
12          tagonist at a correctional facility, the following are re-  
13          corded:

14                 “(1) The location of the administration.

15                 “(2) The time of the administration.

16                 “(3) The name of the individual that the opioid  
17                 antagonist was administered to.

18                 “(4) The name and title of the person that ad-  
19                 ministered the opioid antagonist and the status of  
20                 the individual to whom the opioid antagonist was ad-  
21                 ministered.

22          “(d) NO LIABILITY FOR ADMINISTRATION.—No in-  
23          carcerated person may be held liable for the administra-  
24          tion of an opioid antagonist kit in good faith.

1       “(e) REPORT.—The Director of the Bureau of Pris-  
2       ons shall submit a report each year to Congress detailing  
3       compliance with the requirements of this section, includ-  
4       ing—

5               “(1) the amount of opioid antagonists available  
6       at each correctional facility;

7               “(2) the number of opioid overdoses at each  
8       such facility;

9               “(3) the number of trainings under subsection  
10       (b) at each such facility; and

11              “(4) the number of expired opioid antagonist  
12       kits.

13       “(f) DEFINITIONS.—In this section:

14              “(1) The term ‘opioid antagonist’ means a  
15       medication approved by the Federal Food and Drug  
16       Administration that, when administered, neutralizes  
17       in whole or in part the pharmacological effects of an  
18       opioid in the human body.

19              “(2) The term ‘opioid overdose prevention kit’  
20       means a kit containing—

21                      “(A) an opioid antagonist; and

22                      “(B) a pamphlet or other written notice  
23       that provides guidance on how to recognize the  
24       signs or symptoms of an opioid overdose and

1 identifies the steps to take in response to a sus-  
2 pected opioid overdose.

3 “(3) The term ‘personnel’ includes correctional  
4 officers, medical staff, counselors, and other employ-  
5 ees of the Bureau of Prisons.

6 “(g) AUTHORIZATION OF APPROPRIATIONS.—There  
7 are authorized to be appropriated:

8 “(1) for fiscal year 2026, \$6,000,000, for train-  
9 ing, purchase of opioid antagonists, and the initial  
10 report;

11 “(2) for each of fiscal years 2027 and 2028,  
12 \$2,000,000, for maintenance of opioid antagonist  
13 kits and training, and for additional reporting on the  
14 effectiveness of the program.”; and

15 (2) in the table of sections for such chapter, by  
16 adding at the end the following:

“4052. Availability of opioid antagonists.”.

○